Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | DDX3X | O00571 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647864 | 0.94 | CDK2 (0.36) | CDK2CCNE2CCNE1MKNK1CDK1 | |
| SCHEMBL13647850 | 0.88 | POLB (0.39) | CDK2CCNE2CCNE1CDK1AURKA | |
| SCHEMBL13513935 | 0.88 | GSK3B (0.37) | CDK2CDK1MTORSMG1ALDH1A1 | |
| SCHEMBL14489538 | 0.82 | TAAR1 (0.44) | CDK2CDK1AURKAADORA2AALDH1A1 | |
| SCHEMBL2866087 | 0.81 | S1PR1 (0.46) | — | |
| SCHEMBL13647855 | 0.79 | TNK2 (0.36) | CDK2FGFR1MAPK1 | |
| SCHEMBL13513926 | 0.78 | RXFP1 (0.36) | CDK2CCNE2CCNE1GAANPY5R | |
| SCHEMBL13647859 | 0.78 | CDC7 (0.39) | CDK2LMNATSHRMAPTPIM1 | |
| SCHEMBL2860934 | 0.78 | GSK3B (0.38) | AURKAADORA2ALMNACFTREGFR | |
| SCHEMBL2854241 | 0.78 | SYK (0.37) | CDK2CCNE1MAPTRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226920-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | CDK2 31/4885CCNE2 1739/4885CCNE1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.